TVI AST 008 Randomized controlled Phase 2b clinical trial to evaluate the safety and efficacy of TVI-Brain-1 combined with conformal radiotherapy and temozolomide compared to standard therapy as a treatment for newly diagnosed O6-methylguanine methyltrans

NCT05685004

Randomized controlled Phase 2b clinical trial to evaluate the safety and efficacy of TVI-Brain-1 combined with conformal radiotherapy and temozolomide compared to standard therapy as a treatment for newly diagnosed O6-methylguanine methyltransferase negative (MGMT unmethylated) grade 4 astrocytoma (glioblastoma multiforme; glioblastoma; GBM).

Associated Conditions

Brain Cancer

Principal Investigator

Sherif Makar

Sponsor

TVAX Biomedical Inc

This clinical trial is being performed because there is a need for safer and more effective treatments for glioblastomas. The purpose of this specific clinical study is to determine how safe and effective TVI-Brain-1 would be as a treatment for newly diagnosed glioblastomas when combined with surgery, radiotherapy and chemotherapy.

This study is currently enrolling.